evipedia.ai
← Back

Methylene Blue for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Methylthioninium Chloride, MB, ProvayBlue, Proveblue, Urolene Blue, Basic Blue 9, C.I. 52015, Swiss Blue, Tetramethylthionine Chloride

Motivation

Methylene blue is a deep-blue synthetic dye that has been used as a medicine for well over a century. Inside cells it can pass electrons along the machinery that produces energy, and this property has drawn people interested in brain health and healthy aging to take it, often as drops or capsules bought online rather than through a pharmacy.

It was one of the first synthetic drugs, given for malaria in the 1890s, and today a prescription injection is approved for a blood disorder in which red blood cells cannot carry oxygen properly. Interest outside the clinic grew after small brain-imaging studies tested single doses on memory and attention, after mouse lifespan testing, and after well-known public figures were seen using it.

This review examines what human trials, animal research and safety reports show about methylene blue for memory, mood and healthy aging. It also covers how the compound interacts with common antidepressants and with an inherited red blood cell enzyme deficiency, and what is known about dosing, product quality and monitoring.

Benefits - Risks - Protocol - Conclusion

The items below give high-level overviews of methylene blue’s proposed mechanisms, human evidence and limits, from priority experts and academic narrative reviews.

Only four items are listed because no further openly accessible overview qualified. Rhonda Patrick’s dedicated methylene blue discussions on FoundMyFitness are members-only episodes whose content is not publicly accessible, so none is listed. Lifespan.io’s only dedicated methylene blue article is a Lifespan.io news report on a single mouse bone study rather than an overview, so it is not listed. No dedicated methylene blue content was found from Chris Kresser or Life Extension Magazine.

Grokipedia

  • Methylene blue

    An encyclopedic overview of chemistry, history, approved use for methemoglobinemia (blood unable to carry oxygen normally) and research on mitochondrial effects, with dose-dependent hemolysis (red blood cell destruction) and serotonin syndrome cautions.

Examine

No Examine article on methylene blue exists. Methylene blue is a prescription drug in its approved form, and Examine.com does not typically cover prescription medications; its site lists only a research-feed summary of a single sunscreen study.

ConsumerLab

Systematic Reviews

The listed systematic reviews cover methylene blue’s best-studied clinical effects and its two principal safety concerns; none addresses healthy-adult cognition or longevity.

Mechanism of Action

Its actions mostly stem from electron shuttling.

  • Mitochondrial electron cycling: NADPH-dependent enzymes (NADPH is the main cellular electron carrier) reduce it to leucomethylene blue, which passes electrons to cytochrome c, bypassing complexes I and III of the electron transport chain (which makes ATP, the cell’s energy currency). In human connective-tissue cells it raised complex IV (the chain’s final enzyme) activity by 30% and oxygen use by 37–70% (Atamna 2008).
  • Hormetic dose response (opposite effects at low and high doses): Low doses enhance respiration and act as antioxidants; higher doses reverse this (review by Bruchey 2008).
  • Nitric oxide blockade: It inhibits nitric oxide synthase (which makes the vessel-relaxing gas nitric oxide) and guanylate cyclase (the enzyme nitric oxide activates), raising blood pressure (meta-analysis by Pruna 2024).
  • MAO-A inhibition: It potently and reversibly inhibits monoamine oxidase A (MAO-A), with weaker action on MAO-B (a related dopamine-degrading enzyme), explaining serotonin syndrome risk (Ramsay 2007).
  • Pharmacology: Oral bioavailability (share absorbed into blood) is about 72% (Walter-Sack 2009). Half-life is about 24 hours per the US Food and Drug Administration (FDA) label, 5.25 hours in an earlier study (Peter 2000). It is 94% protein-bound, distributes widely, is metabolized mainly by UGT1A4 and UGT1A9 (liver enzymes tagging drugs for excretion), partly by CYP1A2, CYP2C19 and CYP2D6 (drug-metabolizing liver enzymes), is a P-gp (cellular drug-export pump) substrate, and about 40% is excreted unchanged (FDA label).
  • Competing views: Benefits may reflect mitochondrial support or MAO-A inhibition; when light-activated it generates oxygen radicals.

Historical Context & Evolution

  • Origins: Heinrich Caro synthesized methylene blue in 1876 as a textile dye; in the 1890s it became the first synthetic antimalarial and the first fully synthetic drug (reviewed by Lu 2018 and Schirmer 2011).
  • Clinical uses: It later became a registered treatment for methemoglobinemia in most countries (systematic review by Lu 2018); the FDA approved an injectable form, ProvayBlue, for acquired methemoglobinemia in 2016 (FDA label).
  • Psychiatry: In the 1980s, Naylor’s group in Scotland found less depression in bipolar disorder at 300 mg/day than at 15 mg/day (Naylor 1986).
  • Health optimization: Atamna and Ames reported that it delayed senescence (permanent cell-division arrest) in human cells (Atamna 2008), and Gonzalez-Lima’s group framed low doses as a memory enhancer, leading to controlled human memory trials (Telch 2014).
  • Dementia: TauRx, the developer of a related compound, ran Alzheimer’s trials; a positive phase 2 result (Wischik 2015) was followed by a negative phase 3 primary result for the reduced analogue LMTM (leuco-methylthioninium) (Gauthier 2016); a later TauRx phase 3 trial of hydromethylthionine also missed its primary endpoints, which the sponsor attributed to symptomatic activity in its low-dose control arm (Wischik 2026).
  • Longevity testing: The Interventions Testing Program found no median lifespan extension in mice (Harrison 2014); consumer use nonetheless surged in the 2020s through social media.

Expected Benefits

High 🟩 🟩 🟩

Fewer Depressive Symptoms in Bipolar Disorder

Adding methylene blue to mood stabilizers reduced residual depression in two independent double-blind crossover trials: Naylor’s Dundee group (300 mg/day versus 15 mg/day for a year each, with lithium; Naylor 1986) and Alda’s Dalhousie–McMaster group (195 mg/day versus 15 mg/day for 3 months each, with lamotrigine; Alda 2017). Anxiety also fell, without switches into mania. Both trials were small, and the 15 mg/day comparator may itself be active (Naylor 1987), which would shrink rather than inflate differences. Evidence outside bipolar disorder is minimal.

Magnitude: Standardized effect size (difference in standard-deviation units; 0.8 is conventionally large) 0.80 (95% confidence interval [CI, the range likely to contain the true value] 0.27–1.30) on the Montgomery–Åsberg Depression Rating Scale for 195 mg/day versus 15 mg/day among completers (Alda 2017).

Lower Risk of Postoperative Delirium in Older Adults

Intravenous methylene blue (2 mg/kg) given during anesthesia lowered postoperative delirium in randomized trials from two independent groups: Deng’s Fudan University group in older non-cardiac surgery patients (Deng 2021) and pancreatic surgery (Deng 2026), and Zhang’s Xuzhou group in older joint-replacement patients (Zhang 2025). A meta-analysis of three trials confirmed the effect (Taylan 2026). Deng 2021 was open-label. These data concern intravenous use around surgery; no trial has tested oral daily use for this outcome.

Magnitude: Odds ratio (OR, odds of delirium relative to control) 0.35 (95% CI 0.23–0.53) across three trials (Taylan 2026); in Deng 2021, OR 0.24 (95% CI 0.11–0.53), with delirium in 7.3% with methylene blue versus 24.2% with saline.

Malaria Treatment and Transmission Blocking ⭕️ Not Central to Health & Longevity

The first synthetic antimalarial, methylene blue paired with artesunate gave the fastest parasite clearance in Burkina Faso, though a lower day-28 cure than standard artesunate-amodiaquine (Zoungrana 2008); added to dihydroartemisinin-piperaquine in Mali, it cleared gametocytes (the parasite stage that infects mosquitoes) (Dicko 2018). A systematic review found it consistently effective (Lu 2018). This bears on infectious disease, not on aging.

Magnitude: On day 2, none of 20 participants given dihydroartemisinin-piperaquine plus methylene blue infected mosquitoes, versus 13 of 20 (65%) given dihydroartemisinin-piperaquine alone (Dicko 2018).

Blood Pressure Support in Septic and Vasoplegic Shock ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In vasoplegic shock (low blood pressure from excessive vessel relaxation, as in sepsis or after heart surgery), intravenous methylene blue supports pressure by blocking nitric oxide signaling: Kirov’s group in Russia found higher pressure (Kirov 2001), Ibarra-Estrada’s in Mexico faster vasopressor (pressure-raising drug) withdrawal (Ibarra-Estrada 2023). Meta-analyses of perioperative and critical-care trials (Pruna 2024; Fernando 2024, low certainty) reported lower mortality, but one limited to adult shock and 28–30-day mortality did not (Rodríguez-Lima 2026). It bears on critical care. Net reading: blood pressure gains are replicated; survival benefit is uncertain.

Magnitude: Mean arterial pressure (average pressure across the heartbeat cycle) 8.4 mmHg higher than control (95% CI 5.01–11.75); mortality risk ratio (RR, risk relative to control) 0.60 (95% CI 0.43–0.84) across nine trials (Pruna 2024), not confirmed by the later meta-analysis (Rodríguez-Lima 2026).

Local Pain Relief ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Local methylene blue may temporarily disable small pain nerve endings. After hemorrhoid surgery, trials from independent groups in Singapore (Sim 2014) and Iran (Azhough 2024) lowered pain, confirmed by a six-trial meta-analysis (Zhu 2025). A meta-analysis of uncontrolled studies suggests relief in oral mucositis (cancer-therapy mouth sores) (Rondelli 2026) and a disc-injection meta-analysis reported benefit (Guo 2019), but the largest placebo-controlled disc trial found none (Kallewaard 2019). This bears on procedural pain, not aging. Net reading: relief after hemorrhoid surgery is replicated, while benefit at other sites is unestablished.

Magnitude: Pain 1.44 points lower on a 0–10 scale on day 2 after hemorrhoid surgery versus control (95% CI 1.01–1.87) (Zhu 2025); in oral mucositis, a pooled 4.81-point fall (95% CI 4.05–5.57), before-after change with no control group (Rondelli 2026); in the disc trial, treatment success was 35% with methylene blue versus 26.8% with placebo, not statistically significant (Kallewaard 2019).

Medium 🟩 🟩

No benefit sits at Medium: each outcome either has replicated randomized trials from independent groups (High) or rests on conflicted, uncontrolled, indirect or analogue-compound human data (Low).

Low 🟩

Memory and Attention in Healthy Adults ⚠️ Conflicted

Single oral doses increased task-related brain activation on imaging and memory retrieval (Rodriguez 2016) and improved contextual memory (Telch 2014), both from Gonzalez-Lima’s network. The same network’s 12-week trial in older adults posted no between-group analysis (NCT02380573). Net reading: acute gains are unconfirmed with daily use.

Magnitude: Face-name recall in healthy older adults on 282 mg/day rose from 14.5 to 16.7 with methylene blue versus 14.4 to 16.0 with placebo over 12 weeks; not compared between groups (NCT02380573).

Slowing Alzheimer’s Disease Progression ⚠️ Conflicted

In a phase 2 trial funded by TauRx, the developer of a related compound, 138 mg/day slowed decline in moderate disease (Wischik 2015). A phase 3 trial of the reduced analogue LMTM failed its co-primary endpoints (Gauthier 2016). Net reading: benefit is unproven.

Magnitude: 5.42 points less decline than placebo on the ADAS-cog (Alzheimer’s Disease Assessment Scale–cognitive subscale) at 24 weeks in moderate disease (Wischik 2015); LMTM phase 3 differences were −0.02 (95% CI −1.60 to 1.56) and −0.43 (95% CI −2.06 to 1.20) points (Gauthier 2016).

Reversal of Acquired Methemoglobinemia ⭕️ Not Central to Health & Longevity

This approved use converts oxidized hemoglobin back to its oxygen-carrying form after exposures such as benzocaine or nitrites. Approval rests on an uncontrolled single-arm study and registry (FDA label), consistent with long clinical use reviewed by Schirmer 2011. It bears on poisoning emergencies, not aging.

Magnitude: 26 of 28 treated adults (92.9%) had at least a 50% fall in methemoglobin at first post-dose assessment; no control group (FDA label).

Relief of Intractable Anal Itching ⭕️ Not Central to Health & Longevity

Injected around the anus, methylene blue may disable itch-carrying nerve endings in idiopathic pruritus ani (persistent anal itching without known cause). A meta-analysis of seven uncontrolled studies (225 patients) found high resolution rates from poor-quality literature (Jia 2023). This bears on a local skin condition, not aging.

Magnitude: Resolution in 76.1% of patients after a single injection (95% CI 64.9–87.3%); no control group (Jia 2023).

Adjunct to Periodontitis Treatment ⭕️ Not Central to Health & Longevity

Activated by red light, methylene blue kills gum bacteria as an add-on to mechanical cleaning in periodontitis (gum disease). A meta-analysis of 11 randomized trials found less plaque, bleeding and pocket depth, without attachment gain (Alasqah 2024). Evidence is indirect: it was always light-activated. This bears on oral health.

Magnitude: Probing depth standardized mean difference (difference in standard-deviation units) −0.38 (95% CI −0.57 to −0.19) versus cleaning alone; clinical attachment level −0.01 (95% CI −0.21 to 0.19), no difference (Alasqah 2024).

Oral Lichen Planus Symptom Control ⭕️ Not Central to Health & Longevity

Activated by red light, methylene blue was compared with corticosteroids for oral lichen planus (a chronic inflammatory mouth condition). A meta-analysis of five randomized trials found similar pain, lesion size and response, from heterogeneous studies (Waingade 2022). Evidence is indirect: it was always light-activated. This bears on oral health.

Magnitude: Complete response risk ratio 0.89 (95% CI 0.54–1.38) and pain score difference −2.02 (95% CI −5.96 to 1.92) versus corticosteroids, neither statistically significant (Waingade 2022).

Speculative 🟨

Delayed Cellular Senescence and Skin Aging

Cultured human connective-tissue cells treated with methylene blue divided more than 20 extra times before senescence (Atamna 2008), and 3D skin models showed better hydration and dermal thickness (Xiong 2017). The basis is laboratory only.

Lifespan Extension

In the Interventions Testing Program, methylene blue did not change median mouse lifespan, with only a 6% gain in female maximum lifespan (Harrison 2014); bone aging was unaffected (Poudel 2024). The basis is animal only.

Neuroprotection After Stroke

In rats with permanent stroke, methylene blue delayed loss of at-risk brain tissue but did not reduce final infarct size (area of dead brain tissue) (Rodriguez 2014). The basis is animal only.

Benefit-Modifying Factors

  • Genetic polymorphisms: G6PD variants mainly alter risk, but people with deficiency may not convert methylene blue to its active reduced form, so benefit may be smaller (FDA label). No other genotype has been linked to response.
  • Baseline biomarkers: Mechanistic work predicts larger gains when mitochondrial function is impaired; the 12-week trial expected greater effects in mild cognitive impairment than in healthy aging but posted no between-group analysis (NCT02380573). No baseline marker predicts response.
  • Sex: No sex differences in human benefit have been reported; in mice, the small maximum-lifespan gain occurred only in females (Harrison 2014).
  • Pre-existing conditions: Mood benefits come mainly from bipolar disorder on mood stabilizers (Alda 2017); one small trial found 15 mg/day effective in severe depression (Naylor 1987). People whose fear persisted after exposure therapy tended to fare worse with methylene blue (Telch 2014).
  • Age: Delirium benefits were shown in older surgical patients (Deng 2021); the 12-week cognition trial enrolled adults aged 45–89 but posted no analysis by age (NCT02380573). Lower kidney clearance in older adults raises exposure (FDA label).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Blue-Green Discoloration of Urine and Skin

Methylene blue is excreted in urine, turning it blue-green, and larger doses tint skin, mucous membranes and stool. Discoloration was recorded in malaria trials by the Bamako–San Francisco–Radboud group (Dicko 2018) and across studies reviewed by the Heidelberg group (Lu 2018). It is harmless but can interfere with urine dipstick tests that rely on a blue indicator (FDA label).

Magnitude: Blue urine in 19 of 20 participants given methylene blue versus 0 of 20 given the same antimalarial without it (Dicko 2018).

Blood Pressure Elevation

By blocking nitric oxide-mediated vessel relaxation, methylene blue raises blood pressure, and hypertension is listed among class adverse reactions (FDA label). Randomized trials from independent groups in Russia (Kirov 2001) and Turkey (Memis 2002) found higher mean arterial pressure with intravenous use, confirmed by meta-analyses (Pruna 2024; Fernando 2024). These trials enrolled critically ill and surgical patients, in whom the rise is intended; no trial has measured blood pressure in healthy oral users.

Magnitude: Mean arterial pressure 8.4 mmHg higher than control (95% CI 5.01–11.75) in critically ill and perioperative patients (Pruna 2024) and 10.2 mmHg higher at 6 hours in septic shock (95% CI 6.1–14.2) (Fernando 2024); no figure exists for healthy users.

Medium 🟥 🟥

Serotonin Syndrome With Serotonergic Drugs

Serotonin syndrome causes agitation, fever, tremor, rigidity and seizures, and arises because methylene blue potently inhibits MAO-A (Ramsay 2007). A systematic review of case reports and retrospective surgical audits found reactions after intravenous use clustered in people taking serotonin reuptake inhibitors (Ng 2010), and small doses have also triggered it (Schwiebert 2009). The FDA label carries a boxed warning noting fatal cases (FDA label). Risk at low oral doses is unquantified.

Magnitude: Of 26 reported confusional reactions, 24 occurred in people taking a serotonin reuptake inhibitor and one with clomipramine; the review reports no incidence, no control group (Ng 2010).

Hemolytic Anemia, Especially in G6PD Deficiency

Oxidant stress from methylene blue can destroy red blood cells, most readily in G6PD deficiency, where the label contraindicates use; single doses of 20 mg/kg or more have caused severe hemolysis and death (FDA label). A pooled analysis of four Heidelberg–Nouna malaria trials found lower hemoglobin in fully deficient children at 15 mg/kg/day (Müller 2013); an uncontrolled study found no hemolysis in 74 deficient men with milder African variants (Mandi 2005). These doses far exceed typical consumer use.

Magnitude: 2 hemolysis episodes occurred among 1,005 children, both among the 844 given methylene blue and none among the 161 not given it (Müller 2013).

Gastrointestinal and Urinary Irritation ⚠️ Conflicted

Nausea, vomiting, abdominal pain and painful urination are the most frequent dose-related complaints. At 20 mg/kg/day, far above consumer doses, methylene blue regimens caused more mild vomiting and painful urination than standard malaria therapy (Zoungrana 2008), and a review of oral use found mild effects rose with dose (Tariq 2021). In a Mali trial, adverse events other than blue urine did not differ from control (Dicko 2018). Net reading: mild digestive and urinary symptoms are likely at high doses and uncertain at low doses.

Magnitude: Nausea in 4 of 20 versus 1 of 20 and vomiting in 2 of 20 versus 4 of 20 with versus without methylene blue (Dicko 2018); serious adverse events in 3 of 1,902 oral users (0.16%), no control group (Tariq 2021).

Postoperative Fever After Intravenous Use

In older adults given 2 mg/kg intravenously during joint replacement, postoperative fever was more common than with a glucose-solution control, while other adverse events were similar (Zhang 2025). The evidence is a single trial in surgical patients, the mechanism is unknown, and no data exist for oral use.

Magnitude: Fever in 16.5% with methylene blue versus 7.4% with control (P = 0.039, a probability value below 0.05 that marks the difference as statistically significant) (Zhang 2025).

Low 🟥

Hypersensitivity and Anaphylaxis

Severe allergic reactions, including anaphylaxis (life-threatening whole-body allergy), are reported with methylene blue class products, and a prior severe reaction contraindicates use (FDA label). A review of dye use in gynecologic laparoscopy (keyhole abdominal surgery) found 13 allergy-like cases (Akazawa 2019).

Magnitude: Not quantified in available studies. Only case reports exist, so no incidence can be derived.

Fetal Harm in Pregnancy

Injection into the amniotic fluid during the second trimester was associated with neonatal intestinal atresia (blocked bowel) and fetal death, and oral doses caused malformations in rats and rabbits (FDA label; review by Cragan 1999). Human data on oral use in pregnancy are lacking.

Magnitude: Not quantified in available studies. Human evidence consists of case reports and series after intra-amniotic injection, without an exposed population suitable for estimating an oral-use rate.

High-Dose Toxicity

Cumulative intravenous doses of 7 mg/kg or more caused nausea, chest pain, rapid heart rate, breathlessness, tremor, confusion and mild methemoglobinemia; single doses of 3 mg/kg or more lowered blood pressure and oxygenation (FDA label). A review of oral use found adverse effects rise with dose (Tariq 2021).

Magnitude: Effects lasted 2–12 hours after cumulative intravenous doses of 7 mg/kg or more; no control group (FDA label).

Headache, Myoclonus, Seizure-Like Events and Low Electrolytes

In the label’s 31-patient study, reactions in ≥2% included headache, low potassium and magnesium, diarrhea, myoclonus (brief involuntary muscle jerks) and seizure-like events, one serious; dizziness and blurred vision prompt a driving caution (FDA label). With analogue hydromethylthionine, headache was most frequent (Wischik 2026), indirect evidence by compound.

Magnitude: The label reports these reactions only as ≥2% in its 31-patient study, which had no control group (FDA label); over the 52-week double-blind phase, headache occurred in 4.5% of hydromethylthionine-treated participants versus 2.8% with the low-dose methylthioninium control (Wischik 2026).

Falsely Low Pulse-Oximetry Readings

The dye absorbs light used by pulse oximeters (finger oxygen sensors), producing falsely low readings without true oxygen loss (FDA label). After intravenous doses during aortic surgery, readings dropped sharply and recovered within minutes (Rong 2019).

Magnitude: Median 49% drop in displayed oxygen saturation within 1 minute, recovering after a median of 270 seconds; no control group (Rong 2019).

Phototoxicity

As a light-activated dye, methylene blue can sensitize skin to light; phototoxicity is listed among class adverse reactions (FDA label), and a case report describes a sunburn-like reaction after surgical use under intense blue operating light (Lambrecht 2012). Its authors linked this to high doses plus intense blue light.

Magnitude: Not quantified in available studies. Only a case report and label listings exist.

Skin Necrosis at Injection Sites

Injected into or leaking under the skin, methylene blue can damage tissue; the label lists necrotic ulcer among class adverse reactions (FDA label). After 1% dye injected under the areola before breast reconstruction, skin necrosis required surgical repair in a case series (Lee 2014). Oral use avoids this.

Magnitude: Skin necrosis in 5 of 35 reconstructed breasts (2 partial, 3 wide); no control group (Lee 2014).

Speculative 🟨

Genotoxicity and Rodent Carcinogenicity

Methylene blue caused DNA mutations in bacterial and hamster-cell assays, and a two-year rat study found pancreatic islet tumors in males (FDA label). No human cancer data exist; the basis is laboratory and animal only.

Impaired Cognition at Higher Doses

A review of animal work describes an inverted dose curve in which higher doses lower complex IV activity and responses below control (Bruchey 2008). The basis is mechanistic and animal only.

Risk-Modifying Factors

  • Genetic polymorphisms: G6PD deficiency, common with African, Mediterranean, Middle Eastern and Asian ancestry, sharply raises hemolysis risk; severity depends on the variant, and milder African variants tolerated 780 mg over 3 days (Mandi 2005).
  • Baseline biomarkers: Low G6PD activity, pre-existing anemia and reduced eGFR (estimated glomerular filtration rate, a measure of kidney filtering) raise risk; total exposure rose 52%, 116% and 192% with mild, moderate and severe kidney impairment (FDA label).
  • Sex: G6PD deficiency is X-linked, so affected men express full deficiency while carrier women vary; one hemolysis episode occurred in a carrier girl (Müller 2013). Pregnancy and breastfeeding carry separate label restrictions.
  • Pre-existing conditions: Depression or anxiety treated with serotonergic drugs, pain treated with opioids, liver impairment (slower clearance) and kidney disease raise risk (FDA label).
  • Age: Older adults more often take serotonergic drugs and have reduced kidney function; the label advises the fewest doses in elderly patients (FDA label).

Key Interactions & Contraindications

Documented interactions:

  • SSRIs and SNRIs (antidepressants blocking serotonin and noradrenaline recycling: sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine): Avoid. Serotonin syndrome, sometimes fatal (FDA label; systematic review by Ng 2010). The label advises no serotonergic drug within 72 hours after the last dose.
  • Other serotonergic drugs (MAO inhibitors such as phenelzine and tranylcypromine, clomipramine, bupropion, buspirone, mirtazapine, linezolid): Avoid. Serotonin syndrome; the antibiotic linezolid is itself an MAO inhibitor (FDA label). The same 72-hour separation applies.
  • Opioids (tramadol, meperidine, methadone, fentanyl): Avoid. Listed in the boxed warning for serotonin syndrome (FDA label); non-serotonergic pain relief avoids the combination.
  • Dextromethorphan (over-the-counter cough suppressant): Avoid. Serotonin syndrome risk; a pharmacokinetic study (drug-level measurement) found no change in dextromethorphan exposure, so the concern is additive serotonin activity (FDA label); dextromethorphan-free cough products avoid it.
  • Midazolam, caffeine and warfarin (substrates of CYP3A4, CYP1A2 and CYP2C9, further drug-metabolizing enzymes): No interaction found; a 2 mg/kg intravenous dose did not change their exposure (FDA label).
  • Chloroquine (antimalarial): Higher methylene blue plasma levels (Walter-Sack 2009) and 35% lower exposure to chloroquine’s metabolite (Rengelshausen 2004), judged not clinically relevant; monitoring for dose-related side effects mitigates this.
  • Artesunate (antimalarial): Higher exposure to its active metabolite dihydroartemisinin (1,246 versus 917 ng·h/mL) and stronger antimalarial activity, without changes in amodiaquine levels (Anh 2020); monitoring for dose-related side effects mitigates this.
  • Triptans (migraine drugs: sumatriptan, rizatriptan): Avoid. Serotonin syndrome; the label names migraine medications among serotonergic agents raising this risk (FDA label). The same 72-hour separation applies.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Serotonergic supplements (St John’s wort, 5-HTP [5-hydroxytryptophan, a serotonin precursor], L-tryptophan, SAMe [S-adenosylmethionine]): Additive serotonergic activity could precipitate serotonin syndrome. Separating use by at least 72 hours mirrors label guidance for serotonergic drugs.
  • Tyramine-rich foods (tyramine, a food compound that can raise blood pressure: aged cheese, cured meats, tap beer): Gut MAO-A inhibition could raise tyramine absorption and blood pressure; reversible inhibition likely limits this. Moderating intake around dosing mitigates it.
  • Oxidant drugs (dapsone, primaquine, rasburicase, nitrofurantoin): Additive oxidative stress could cause hemolysis, especially with G6PD deficiency; hemoglobin checks mitigate this.
  • Nitrates and PDE5 inhibitors (vessel-relaxing heart, erectile-dysfunction and pulmonary-pressure drugs: nitroglycerin, sildenafil, tadalafil): Guanylate cyclase blockade could blunt their vessel-relaxing effect, reducing efficacy.
  • UGT1A4 or P-gp substrates (lamotrigine, digoxin): Inhibition of these elimination pathways, seen in laboratory assays, could raise their blood levels; drug-level monitoring mitigates this.
  • Photosensitizing drugs and light therapy (doxycycline, isotretinoin, red or near-infrared light): Additive light sensitization could cause skin reactions; sun protection and test exposures mitigate this.

Populations who should avoid Methylene Blue:

  • G6PD deficiency: Contraindicated because of hemolytic anemia (FDA label).
  • Prior severe hypersensitivity to methylene blue or other thiazine dyes: Contraindicated (FDA label).
  • People taking serotonergic drugs or opioids: Boxed warning for serotonin syndrome (FDA label).
  • Pregnancy: Fetal harm (FDA label).
  • Breastfeeding: The label advises stopping breastfeeding during and for up to 8 days after treatment (FDA label).
  • Moderate or severe kidney impairment (eGFR 15–59 mL/min/1.73 m²): The label limits use to a single 1 mg/kg dose (FDA label).
  • Liver impairment: The label requires extended monitoring because clearance is delayed (FDA label).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • G6PD test before first use: Prevents hemolytic anemia; the label contraindicates use with deficiency (FDA label).
  • Medication and supplement screen: Prevents serotonin syndrome by identifying serotonergic drugs, opioids and supplements; the label advises no serotonergic drug within 72 hours after the last dose (FDA label).
  • Stopping at warning signs: Agitation, tremor, muscle twitching, sweating or fever signal possible serotonin syndrome, which the label manages by discontinuation and supportive care (FDA label).
  • Lowest effective dose with food: Limits digestive and urinary irritation and dose-dependent toxicity; food before dosing reduced vomiting in a malaria trial (Zoungrana 2008).
  • Blood count during sustained use: Detects hemolysis; hemoglobin at 1–2 weeks, then every 3 months; anemia onset may be delayed a day or more (FDA label).
  • Kidney function check: Prevents excess exposure; the label limits dosing at eGFR below 60 mL/min/1.73 m² (FDA label).
  • Pregnancy avoidance: Prevents fetal harm; reliable contraception during use for those who could become pregnant.
  • Disclosure before procedures: Informing clinicians prevents misread pulse-oximetry and anesthesia-depth monitoring (FDA label) and serotonergic anesthesia-drug combinations.
  • Sun protection: Limits phototoxic skin reactions during the first days of use and after dose increases.

Therapeutic Protocol

Doses below are cited to their source; other parameters (timing, splitting, titration, cycling) reflect common practice unless cited.

  • No longevity regimen tested: No human trial has tested methylene blue for lifespan or healthspan; all doses below come from cognition, mood or disease trials.
  • Single-dose cognition approach: 260 mg orally after an exposure session (Telch 2014) or a single low dose about one hour before testing (Rodriguez 2016); popularized by Francisco Gonzalez-Lima (Attia podcast #38).
  • Daily cognition approach: 282 mg/day for 12 weeks in healthy aging and mild cognitive impairment (NCT02380573); 138 mg/day in Alzheimer’s disease (Wischik 2015).
  • Daily mood approach: 195 mg/day added to lamotrigine (Alda 2017) or 300 mg/day added to lithium (Naylor 1986).
  • Low doses: 15 mg/day served as the control in bipolar trials (Alda 2017), yet showed antidepressant effects in severe depression (Naylor 1987); smaller consumer “microdoses” are untested.
  • Competing approaches: Conventional medicine reserves it for approved and hospital uses; integrative and self-directed users take low daily oral doses; psychiatrist Chris Palmer, who has not prescribed it, warns that too little and too much can harm (Huberman Lab episode).
  • Time of day: Morning or early-day dosing with food is common; food reduced vomiting (Zoungrana 2008), and no study has examined sleep effects.
  • Half-life: About 24 hours per the label (FDA label), versus 5.25 hours in an earlier study (Peter 2000); once-daily dosing can accumulate over several days.
  • Single versus split dosing: Single doses were used for acute cognition testing; splitting daily amounts is common to reduce digestive irritation.
  • Genetic polymorphisms: G6PD status determines eligibility; no pharmacogenetic dose adjustment exists, and UGT1A4, UGT1A9 and CYP2D6 variants are untested.
  • Sex: No sex-specific dosing exists; pregnancy and breastfeeding restrictions apply (FDA label).
  • Age: The 12-week trial used 282 mg/day in adults up to 89 without age adjustment (NCT02380573); the label advises the fewest doses in elderly patients because of reduced kidney clearance.
  • Baseline biomarkers: G6PD activity, eGFR and hemoglobin determine eligibility and dose limits; no biomarker predicts benefit.
  • Pre-existing conditions: Bipolar disorder on lamotrigine or lithium was well tolerated in trials; kidney impairment limits dosing (FDA label); serotonergic treatment for depression excludes use.

Discontinuation & Cycling

  • Short-term or lifelong: Most human data cover single doses to 12 weeks, with one two-year bipolar trial (Naylor 1986); lifelong use is unstudied.
  • Withdrawal effects: No withdrawal syndrome has been reported in trials, including a crossover design that stepped active dosing down to 15 mg/day over one week (Alda 2017).
  • Tapering: Not required pharmacologically; before starting a serotonergic drug, the label advises a 72-hour gap after the last dose (FDA label).
  • Cycling: No evidence shows cycling maintains efficacy; some users cycle (for example, weekdays on, weekends off) to limit cumulative exposure, a common-practice rationale given the hormetic dose curve.

Sourcing and Quality

  • Pharmaceutical grade: United States Pharmacopeia (USP) grade methylene blue meets compendial purity standards; industrial, laboratory, “chemical” and aquarium grades are not made for human use and may contain heavy metals or other dyes.
  • Approved and compounded forms: ProvayBlue (American Regent) is the FDA-approved injection (FDA label); oral capsules are made from USP-grade powder by compounding pharmacies (for example, Empower Pharmacy) on prescription.
  • Consumer drops and capsules: Products sold as supplements are not the labeled ProvayBlue injection, the approved product (FDA label); concentration (a 1% solution is 10 mg/mL) and purity vary, so a certificate of analysis and third-party heavy-metal testing are key checks.
  • Impurities: The label notes azure B as a minor impurity and metabolite with 8-fold lower potency than methylene blue (FDA label).
  • Formulation: Aqueous oral solutions showed high bioavailability (Walter-Sack 2009), whereas the highest tablet dose in an Alzheimer’s trial was limited by poor dissolution and absorption (Wischik 2015).

Practical Considerations

  • Time to effect: Brain-activity and memory changes were measured one hour after a single dose (Rodriguez 2016); mood changes emerged within 3-month treatment periods (Alda 2017).
  • Common pitfalls: Combining it with antidepressants, using non-pharmaceutical dye, skipping a G6PD test, assuming higher doses work better despite the hormetic curve, and mistaking blue urine for illness; concentrated drops also stain teeth and fabric.
  • Regulatory status: In the US, the injection is prescription-only and approved for acquired methemoglobinemia (FDA label); every other use is off-label, and consumer oral products fall outside that labeled injection.
  • Cost and accessibility: Methylene blue is inexpensive and widely available; compounded prescriptions cost more but remain modest.
  • Research funding incentives: As an off-patent generic it lacks a sponsor for large trials, whereas industry funding flowed to TauRx’s patented analogue; for dementia, payers facing costly newer drugs would gain from a cheap effective option, so payer bias against it is unlikely.

Interaction with Foundational Habits

  • Sleep: None documented; possibly indirect. No study has measured sleep; monoamine oxidase inhibition and reported dizziness or confusion (FDA label) could affect it, so morning dosing is common practice, and tracking sleep quality after starting identifies individual effects.
  • Nutrition: Direct. Taking doses after food reduced vomiting (Zoungrana 2008). No nutrient depletion is known; large amounts of tyramine-rich foods (aged cheese, cured meats) are theoretically worth moderating because of MAO-A inhibition.
  • Exercise: None documented. The mitochondrial mechanism suggests possible effects on exercise metabolism, but no human exercise trial exists; pulse-oximeter readings during training or altitude exposure may read falsely low, as the label warns (FDA label); the drop was measured after intravenous doses (Rong 2019).
  • Stress management: Potentiating, context-dependent. Given after a successful exposure session it strengthened retention of reduced fear, but tended to worsen outcomes after unsuccessful sessions (Telch 2014); it also reduced anxiety in bipolar disorder (Alda 2017).

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes eligibility and reference values: a quantitative G6PD test, a complete blood count, kidney and liver function, and resting blood pressure, alongside a full review of prescription drugs, over-the-counter products and supplements for serotonergic agents. Recording baseline mood, memory and energy with repeatable measures allows later comparison against the individual’s own starting point.

Ongoing monitoring follows this cadence: hemoglobin and hemolysis markers at 1–2 weeks, then every 3 months during daily use; kidney and liver tests every 6–12 months; blood pressure at home during the first week and after dose increases. Any agitation, tremor or fever prompts immediate review. Success means a measurable improvement in the targeted marker without hemoglobin decline, side effects or interactions.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
G6PD activity 7.0–20.5 U/g hemoglobin (standard reference range) Safety check: deficiency stops use Once at baseline; contraindication per FDA label; ranges vary by laboratory; recent hemolysis or transfusion can mask deficiency
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range) Safety check: a fall signals hemolysis Part of the complete blood count; no fasting needed; anemia may appear a day or more after dosing per FDA label
Indirect bilirubin and haptoglobin Indirect bilirubin 0.2–0.8 mg/dL; haptoglobin 30–200 mg/dL (standard reference range) Safety check: rising bilirubin or falling haptoglobin signals hemolysis Pair with hemoglobin; label lists these laboratory signs of hemolysis (FDA label)
eGFR ≥60 mL/min/1.73 m² (standard reference range) Safety check: low values limit dosing Creatinine-based; label limits dosing at 15–59 mL/min/1.73 m² (FDA label)
ALT 7–56 U/L (standard reference range) Safety check: liver injury changes use ALT (alanine aminotransferase, a liver enzyme); label lists elevated liver enzymes and delayed clearance in liver impairment (FDA label); pair with AST (aspartate aminotransferase, another liver enzyme that leaks into blood when liver cells are damaged)
Methemoglobin 0–1.5% of total hemoglobin (standard reference range) Safety check: high-dose toxicity Co-oximetry (laboratory light-absorption blood test) only when symptoms occur; pulse oximetry is unreliable after dosing (FDA label)
Blood pressure No established target; track change from own baseline Safety check: a rise changes use Home readings before and 1–2 hours after dosing in the first week; label lists hypertension (FDA label)

Qualitative markers:

  • Mood: A validated questionnaire such as the Patient Health Questionnaire-9, compared with baseline.
  • Memory and attention: A repeatable cognitive test or a structured self-rating, compared with baseline.
  • Energy and fatigue: Daily self-rating during the first month.
  • Sleep quality: Sleep onset, awakenings and morning alertness.
  • Side effects: Expected blue urine; digestive upset, headache, dizziness, skin reactions; agitation, tremor or fever as stop signals.

Emerging Research

  • Septic shock survival trial (NCT06481410): Recruiting, 488 participants, primary endpoint 28-day survival, completion expected 2027. A positive result would resolve the survival conflict in favor of benefit; a null result would confirm that the shock benefit is limited to blood pressure.
  • Immunotherapy neurotoxicity study (NCT07169487): Phase 1, 18 participants, recruiting; intravenous methylene blue for inflammatory and neurological complications of cell therapy. A positive result would add human anti-inflammatory brain data; a null result would leave the conclusion unchanged.
  • MB2 healthy-aging trial (NCT02380573): Completed 2023, 117 participants; results posted 2024 without between-group analysis, showing similar changes with methylene blue and placebo, as cited in the memory item.
  • DREAM brain-imaging study (NCT07866833): Completed 2025, 53 participants (schizophrenia and healthy volunteers), intravenous methylene blue versus placebo during a working-memory task; no results posted.
  • Perioperative brain protection: A second systematic review of intravenous use in non-cardiac surgery (Garo 2026) examines the delirium question; all trials so far come from China, and replication elsewhere could strengthen or weaken that item.
  • Alzheimer’s analogue: TauRx reports later separation in mild cognitive impairment with hydromethylthionine (Wischik 2026); independent replication could strengthen, and sponsor-only analyses weaken, the dementia case.
  • Aging biology: Negative mouse bone and lifespan data (Poudel 2024; Harrison 2014) weaken, while cell senescence data (Atamna 2008) support, the longevity rationale; no human aging-biomarker trial exists.

Conclusion

Methylene blue is an old, inexpensive dye turned medicine whose appeal for healthy aging rests on its ability to shuttle electrons inside cells and support energy production. Its approved medical use is correcting a blood disorder, and its strongest trial evidence lies in settings far from everyday longevity practice: treating malaria, raising dangerously low blood pressure in intensive care, easing local pain, and lowering the chance of confusion after major surgery in older adults.

For mood, small trials from two independent groups found less lingering depression when it was added to standard bipolar treatment. For memory in healthy people, early single-dose findings come from one research network and were not clearly confirmed with daily use, and dementia results are mixed and tied to TauRx, a company developing a related compound. Claims about slowing aging itself rest on cell and animal work, and the main mouse lifespan study found little effect.

The risks are concrete. It can trigger a dangerous serotonin reaction with many common antidepressants and some pain medicines, can destroy red blood cells in people with an inherited enzyme deficiency, may harm a developing baby, and turns urine blue. Products sold outside pharmacies vary in quality. Overall, the evidence is broad but thin where a longevity-focused audience’s interest lies, effects depend strongly on dose in both directions, and company funding is concentrated in the dementia research.

Top - Benefits - Risks - Protocol